Health Policy Affairs

On Nov. 5, 2025, SIR submitted comments to Palmetto GBA on its proposed local coverage determination (LCD) for irreversible electroporation (IRE) for cancer, emphasizing the growing body of evidence supporting IRE as a safe and effective treatment option for select patients with prostate and pancreatic cancers. We urge Palmetto to consider coverage for IRE in appropriately selected patients, particularly when performed in structured clinical settings, registries or high-volume centers. SIR remains committed to advocating for evidence-based coverage policies that expand patient access to minimally invasive, image-guided therapies.